Experts outline ramifications of revised European bioequivalence studies guideline

VRM and Cyton review of the revised European bioequivalence studies guideline
15 August, 2019

This article titled ‘Experts Outline Ramifications of Revised European Bioequivalence Studies Guideline’ was co-written by Cyton Germany’s Cemile Jakupoglu and Maggie Fisher DVM of Veterinary Research Management (VRM) – one of Cyton’s strategic partners. The article analyses the changes made in the updated EU bioequivalence guideline (CVMP revision 3 of Guideline on the conduct of bioequivalence studies for veterinary medicinal products). The long-awaited revision came into effect on 1st July 2019, and provides a greater level of detail as well as clarifying the relevant guidance for companies designing and carrying out BEQ studies.

This article was originally published in Animal Pharm online on August 15th 2019.​

Business Units: 

Clinical Expertise for the
Development and Registration
of your Veterinary Medicines

To find out more about how VRM
is working with Cyton to provide
a complete clinical service, please
visit the website: